Related Experiment Video
Updated: Apr 30, 2026
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
Published on: June 9, 2022
Performance of the OraQuick HCV rapid antibody test for screening exposed patients in a hepatitis C outbreak
Fengxiang Gao1, Elizabeth A Talbot2, Carol H Loring1
1Public Health Laboratories, Division of Public Health Services, New Hampshire Department of Health and Human Services, Concord, New Hampshire, USA.
During a nosocomial hepatitis C outbreak, emergency public clinics employed the OraQuick HCV rapid antibody test on site, and all results were verified by a standard enzyme immunoassay (EIA). Of 1,157 persons, 1,149 (99.3%) exhibited concordant results between the two tests (16 positive, 1,133 negative). The sensitivity, specificity, positive predictive value, and negative predictive value were 94.1%, 99.5%, 72.7%, and 99.9%, respectively. OraQuick performed well as a screening test during an outbreak investigation and could be integrated into future hepatitis C virus (HCV) outbreak testing algorithms.
During a nosocomial hepatitis C outbreak, emergency public clinics employed the OraQuick HCV rapid antibody test on site, and all results were verified by a standard enzyme immunoassay (EIA). Of 1,157 persons, 1,149 (99.3%) exhibited concordant results between the two tests (16 positive, 1,133 negative). The sensitivity, specificity, positive predictive value, and negative predictive value were 94.1%, 99.5%, 72.7%, and 99.9%, respectively. OraQuick performed well as a screening test during an outbreak investigation and could be integrated into future hepatitis C virus (HCV) outbreak testing algorithms.
